Efficacy Mechanism of N-acetylcysteine in Patients With Posttraumatic Stress Disorder
Status:
Withdrawn
Trial end date:
2016-12-31
Target enrollment:
Participant gender:
Summary
It has been suggested that N-acetylcysteine exerts neuroprotective effects by regulating
neurotransmitters and cell signaling pathways. We hypothesize that oral N-acetylcysteine
augmentation will help reduce symptoms in patients with posttraumatic stress disorder as well
as improve cognitive functions. We also expect that the N-acetylcysteine augmentation will
induce change in structural, functional, and neurochemical aspects of the brain.
In this study, we plan to conduct a randomized, double-blind, placebo-controlled augmentation
study with N-acetylcysteine in addition to escitalopram. We will assess the efficacy and
safety of the N-acetylcysteine augmentation.